Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
brief summary
The purpose of this Medical Access Program (also referred to as an Expanded Access Program in the USA) is to provide access to I-DXd for eligible patients with extensive-stage small cell lung cancer (ES-SCLC) after two or more prior lines of treatment (including at least one platinum-based regimen), and for eligible patients who have no suitable treatment options and are not able to enter a clinical study.
detailed description
A patient enrolled in this MAP can continue treatment until any of the following occurs (whichever comes first):
* Disease progression. * Unacceptable toxicity. * The benefit-risk no longer favors the individual. * I-DXd becomes commercially available in the US, and reimbursement is approved for the treatment of ES-SCLC. * The patient chooses to discontinue treatment. * Withdrawal of consent. * Pregnancy. * Physician discretion. * Death.
official title
Medical Access Program for Ifinatamab Deruxtecan (I-DXd, DS-7300a)